Phase I Study of Everolimus (RAD001) in Combination With Lenalidomide in Patients With Advanced Solid Malignancies Enriched for Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Everolimus (Primary) ; Lenalidomide (Primary)
- Indications Adenocarcinoma; Neuroendocrine tumours; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- 01 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 01 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 16 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017, according to ClinicalTrials.gov record.